Neurosearch A/S Says to Cut Workforce by a Fifth, To Concentrate Resources Behind Main Product Huntington's Disease Drug Huntexil

Published: Jan 11, 2011

Reuters -- Danish biopharma company Neurosearch (NEUR.CO) is to cut costs and 20 percent of its workforce to concentrate resources behind its main product under development, Huntington's disease drug Huntexil.

Back to news